FDA Panel Splits on Whether to Take Sibutramine Off the Market

Idsk -- ADELPHI, Md. (EGMN) – A Food and Drug Administration advisory panel split on whether to recommend that sibutramine be withdrawn from the market because of concerns over its cardiovascular safety.